drugset / Trial / NCT01639222

Human Pharmacology Trial of Calcium-vitamin D3 Tablet in Healthy Participants

NCT01639222

Phase 1 Completed 55 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to demonstrate that the intestinal absorption of calcium from a newly developed calcium carbonate-vitamin D3 chewable tablet formulation increases the amount of calcium excreted in urine and decreases parathyroid hormone (PTH) in serum as compared to baseline.

Timeline

Start
2012-07
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Calcium carbonate Other / unclassified 500 mg Oral
Subject Cholecalciferol Other / unclassified 800 iu Oral